Skip to main content

Centogene CentoMetabolic Panel

Centogene has launched its CentoMetabolic panel, a first-line test for a range of rare genetic metabolic diseases. According to Centogene, the panel combines genetic and biochemical testing, allowing immediate confirmation of and better understanding of a disease's course, enhanced treatment monitoring, and tailored treatment guidance. The panel includes as many as 166 genes and was developed for patients suspected to have a metabolic disorder or presenting complex, overlapping symptoms, a metabolic crisis, or neurological conditions of unknown etiology. The firm said that the panel provides short turnaround times, targets critically ill patients, includes enzyme-activity testing and a continually updating set of biomarkers. 

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.